Browse articles from EyeWorld.org related to AMD. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 36-month results from first-in-human study with shape-changing IOL
➤ New data for recently approved EDOF IOL
➤ Company completes first-in-human robotic cataract surgery
➤ Phase 2 study approved for secondary IOL intended for low-vision patients
➤ Investigational device measures real-time intraoperative aqueous outflow
➤ FDA expands dosing on label for faricimab
➤ Company news
➤ ASCRS news and events
➤ FDA approves new EDOF with limited dysphotopsias
➤ Phase 1/2 12-month data for IOL-based drug delivery system
➤ Topline results from Phase 2a wet AMD study
➤ FDA grants Breakthrough Device Designation to brain implant technology
➤ FDA allows Phase 1/2 trial to begin for investigational cell therapy for familial drusen
➤ ASCRS news and events
➤ Positive results in Phase 3 superiority trial for wet AMD treatment
➤ Dosing begins for first-in-human myopia prevention drop
➤ Pre-NDA meeting with FDA for IOP-lowering drop
➤ Company news
➤ ASCRS news and events
➤ Enrollment complete in Phase 3 trial for wet AMD
➤ Dosing complete in Phase 1/2 trial for retinitis pigmentosa treatment
➤ First patient dosed in gene therapy study for optic nerve disorder
➤ Company news
➤ Study: ‘revolutionary,’ ‘world-first’ treatment for vision-threatening condition restores sight ➤ IDE granted to tissue-based presbyopia solution ➤ Fast Track designation granted for geographic atrophy treatment ➤ Phase 1 results for Stargardt gene therapy ➤ Topline Phase 1b results from study comparing a next-gen treatment to faricimab ➤ Enrolled patients complete dosing in part of trial evaluating X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events
➤ FDA grants IDE for synthetic endothelial layer study
➤ NDA submission for wet AMD treatment advances
➤ Positive feedback moves forward NDA submission plans
➤ Company news
➤ ASCRS news and events
➤ 510(k) clearance granted to auto kerato-refracto tonometer
➤ First patient dosed with gene therapy for Best disease
➤ Long-term data shows therapy delays geographic atrophy progression
➤ Lead gene therapy candidate to treat wet AMD and DME announced
➤ FDA accepts BLA resubmission
➤ Company news
➤ ASCRS news and events
➤ Meeting with FDA to advance therapy for Leber congenital amaurosis
➤ 36-month data from first-in-human bimatoprost-IOL system
➤ 20-week data from study evaluating treatment for patients with macular edema secondary to inflammation
➤ Interim data from Phase 1/2 trial for wet AMD therapy
➤ Company news
➤ ASCRS news and events
➤ Complete response letter issued for low-dose atropine drop
➤ Extension study shows reduced GA growth with intravitreal treatment
➤ Durable, 3-year vision improvements seen with optogenetic therapy
➤ Preclinical data supports long-acting nature of investigational anti-VEGF for wet AMD
➤ Company news
➤ ASCRS news and events
➤ Insulin-based treatment for neurotropic keratitis advances
➤ Study evaluating implantable telescope in patients with late-stage AMD begins
➤ Registrational trial to begin for investigational neuroprotective therapy
➤ Enrollment complete in pivotal trials for wet AMD treatment
➤ ASCRS news and events
